Percheron Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Percheron Therapeutics possède un total de capitaux propres de A$9.4M et une dette totale de A$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont A$14.5M et de A$5.2M.

Informations clés

Ratio d'endettement

AU$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	AU$11.87m
Fonds propres	AU$9.36m
Total du passif	AU$5.17m
Total des actifs	AU$14.53m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de PER ( A$14.5M ) dépassent ses passifs à court terme ( A$5.2M ).

Passif à long terme: Les actifs à court terme de PER ( A$14.5M ) dépassent ses passifs à long terme ( A$15.2K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: PER est sans dette.

Réduire la dette: PER n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: PER dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: PER devrait disposer d'une marge de trésorerie suffisante pour 8 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Percheron Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Recent updates

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.

New minor risk - Shareholder dilution

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

Forecast to breakeven in 2027

High number of new and inexperienced directors

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

New major risk - Financial position

New minor risk - Shareholder dilution

New minor risk - Share price stability

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Less than half of directors are independent

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Forecast to breakeven in 2024

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

New 90-day high: AU$0.20

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines